Patients with atrial fibrillation who are ineligible for oral anticoagulation had 75 percent fewer ischemic strokes and system embolisms if they received the Watchman left atrial appendage occlusion device than if they received aspirin alone.

Health insurers are trying to reach deals with drug companies that tie compensation with what they—or, more precisely, their patients—get.

Two physicians received a total of $500,000 in grants from the Heart Rhythm Society (HRS) and Boehringer Ingelheim Pharmaceuticals to support quality improvement research on atrial fibrillation and stroke prevention.

During the first quarter of 2016, Corindus Vascular Robotics, Inc. increased its revenue to $1.1 million, up from $800,000 in the same period last year. The company also installed two new CorPath systems during the quarter, increasing the installed base to 40 systems, including 37 in the U.S. and three internationally.

After 360 days, 98 percent of patients who were implanted with Boston Scientific’s subcutaneous implantable defibrillator (S-ICD) system were free from complications, according to a multi-national registry.

A retrospective analysis found Hispanic and African American patients with heart failure had a lower risk of developing atrial fibrillation compared with white patients who had heart failure.

This study builds on the growing body of evidence for managing heart failure using the St. Jude Medical MultiPoint pacing technology for patients not responsive to other therapy options

Men and women who underwent transcatheter aortic valve replacement (TAVR) had similar rates of survival, major adverse cardiovascular events and vascular complications at 30 days, according to a randomized trial.